Nitric oxide induction as a novel immunoepidemiological target in malaria-infected patients from endemic areas of the Islamic Republic of Iran.
OBJECTIVE
Malaria has been prevalent for a long time in Iran and continues to be a health problem despite substantial control programs. In addition to numerous cytokines, nitric oxide (NO) is thought to be a key molecule and a novel target of malaria immunopathology.


METHODS
The objective of this research was to measure reactive nitrogen intermediates (RNI) as stable metabolites of NO induction in plasma of malaria-infected patients in Iran. In this study, 235 blood samples from malaria patients and 80 blood samples from healthy controls were randomly collected from different malarial endemic provinces of Iran, located in southeastern (Sistan & Balouchestan, Hormozgan, Kerman) and northwestern (Ardabil) areas. The involvement of NO in malaria patients has been investigated by statistical analysis of RNI values. Griess micro assay (GMA) was used during Plasmodium vivax, P. falciparum and mixed infections, in order to evaluate whether RNI changes are related to the provincial areas, parasite strains, clinical symptoms and age and gender parameters.


RESULTS
The results showed a significant increase of RNI level in malaria patients compared with the control groups of Ardabil (p<0.01), Sistan & Balouchestan, Hormozgan and Kerman (p<0.001) provinces. The level of RNI was higher in mixed plasmodial infection than in single infection.


CONCLUSIONS
The high level of RNI was dependent on the type of infection, the plasmodia strain, the clinical symptoms, the age groups and the endemic provinces. Although, this study did not clarify the pathogenic and/or protective role of NO in malaria, our findings provide a novel immunoepidemiological aspect of basal NO production in patients with malaria in endemic areas in Iran.
Nahrevanian
H
H
Department of Parasitology, Pasteur Institute of Iran, Tehran, Iran. mobcghn@yahoo.co.uk
Gholizadeh
J
J
Farahmand
M
M
Assmar
M
M
Sharifi
K
K
Ayatollahi Mousavi
S A
SA
Abolhassani
M
M
D000293:Adolescent; D000328:Adult; D016022:Case-Control Studies; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D007492:Iran / Q000453:epidemiology; D008288:Malaria / Q000097:blood* / Q000453:epidemiology / Q000276:immunology; D016778:Malaria, Falciparum / Q000097:blood / Q000453:epidemiology / Q000276:immunology; D016780:Malaria, Vivax / Q000097:blood / Q000453:epidemiology / Q000276:immunology; D008297:Male; D008875:Middle Aged; D009569:Nitric Oxide / Q000096:biosynthesis* / Q000097:blood; D026361:Reactive Nitrogen Species / Q000097:blood
D026361:Reactive Nitrogen Species; D009569:Nitric Oxide